OptiScan (OIL) 2023年年度报告「ASX」.pdf

1、Optiscan Imaging LimitedAppendix 4EPreliminary final report1.Company detailsName of entity:Optiscan Imaging LimitedABN:81 077 771 987Reporting period:For the year ended 30 June 2023Previous period:For the year ended 30 June 20222.Results for announcement to the market$Revenues from ordinary activiti

2、esup65.9%to1,680,180Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited up2.8%to(4,351,500)Loss for the year attributable to the owners of Optiscan Imaging Limited up2.8%to(4,351,500)DividendsThere were no dividends paid or declared during the current finan

3、cial period.CommentsThe loss for the consolidated entity after providing for income tax amounted to$4,351,500(30 June 2022:$4,233,037).Financial performanceDuring the financial year ending 30 June 2023(FY23),the consolidated entity generated ordinary revenue of$1,680,180from sales,system rentals and

4、 the provision of services,compared to$1,013,039 in the previous corresponding period.The 66%increase in sales revenue was mainly driven by strong demand from Carl Zeiss Meditech(CZM)and the sale of aViewnVivo research device to an American pharmaceutical company.Other income generated for the finan

5、cial year was$968,813(2022:$1,267,208).The Company recorded researchand development incentive income of$737,570(2022:$941,790),a decrease by 21%mainly due to the change in nature of R&D expenses incurred compared to last year.As the Company continues to invest in R&D to accelerate commercialisation,

6、the Company has been able to leverage on external skills,expertise,and access non-dilutive funding through various grant programs.This included$180,103(2022:$294,205)from the BioMedTech Horizons program and$20,000 grant from thethe Australian Government Entrepreneurs Growth Program.Further investmen